Posted: February 1, 2010

Starpharma and Lilly Sign New Drug Delivery Collaboration for Human Pharmaceuticals

(Nanowerk News) Starpharma Holdings Limited today announced the signing of a new agreement with Eli Lilly and Company under which Starpharma's dendrimer drug delivery technology will be applied to enhance compounds in Lilly's human pharmaceutical portfolio.
Under the terms of the agreement Lilly will fund a collaborative research and development program with the aim of creating improved drugs incorporating SPL's proprietary delivery technology, to be commercialised by Lilly.
The agreement announced today relates to the delivery of certain human pharmaceuticals, and is separate and additional to the contract signed in May 2009 in which it was agreed that Starpharma and Elanco (Lilly's animal health division) would work together to develop new animal health products with enhanced properties. The Elanco collaboration continues in its own right.
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at
About Starpharma
Starpharma Holdings Limited is a world leader in the development of dendrimer technology for pharmaceutical, life-science and other applications. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents through licence arrangements with various partners.
In the pharmaceutical field Starpharma is developing VivaGelŪ as a vaginal microbicide and condom coating and has specific programs in the areas of Drug Delivery and Drug Optimisation technologies (using dendrimers to control where and when drugs go when introduced to the body) and Diagnostics. More broadly the company is exploring dendrimer opportunities in materials science applications including water remediation.
Source: Starpharma Holdings (press release)
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: